Inaugural FDA Clearance and Regulatory Competence Acquisition

On September 23, the US Food and Drug Administration granted official commercial marketing authorization for Lyrfigtu, an innovative oncology therapeutic developed by HLB's wholly owned US subsidiary Elevar Therapeutics. The approved drug targets adult patients presenting with previously treated, locally advanced, or metastatic bile duct cancer harboring FGFR2 gene fusions or rearrangements.

This regulatory breakthrough marked HLB’s maiden approval from the US regulatory authority, equipping corporate leadership with indispensable navigational experience across federal inspection frameworks. Celebrating the clearance at corporate headquarters in Seoul, HLB Group Chairman Jin Yang-gon emphasized that the approval confirms the firm’s systematic competence in guiding novel molecular therapeutics through rigorous federal review dossiers.

“What we accomplished is not just a single milestone with a bile duct cancer drug but the foundation and capability to continuously produce new drug successes in the future.” — Jin Yang-gon, HLB Group Chairman

Overcoming Supply Chain Roadblocks for the Rivoceranib Combination

Rivoceranib, an oral VEGFR-2 tyrosine kinase inhibitor, is currently being developed in tandem with Jiangsu Hengrui Pharmaceuticals’ PD-1 inhibitor camrelizumab as a first-line systemic intervention for unresectable hepatocellular carcinoma (HCC). While their global Phase 3 trials demonstrated an unprecedented median overall survival of 23.8 months, regulatory submissions were thwarted three times — in May 2024, March 2025, and July 2026 — primarily due to facility inspection citations.